ScreenerHero

SLN Silence Therapeutics plc

NAS · US · Healthcare · Biotechnology · silence-therapeutics.com
9.820USD-0.10%Mkt Cap: 610.35M $P/E: —

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap610.35M USD
Enterprise Value392.49M USD
Revenue (TTM)615.00K USD
Gross Profit344.00K USD
Net Income (TTM)-88.61M USD
Revenue/Share0.01 USD
Last Price9.820 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees88
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-25.87
PEG—
EV/EBITDA-6.14
EV/Revenue638.20
P/S993.45
P/B12.08
EPS (TTM)-1.29
EPS (Forward)-0.38
52W Range
4.19042% of range17.58
52W High17.58 USD
52W Low4.190 USD
Profitability
Gross Margin61.54%
Oper. Margin-10475.61%
EBITDA Margin0.00%
Profit Margin-15851.88%
ROE-142.23%
ROA-67.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-62.27M USD
CapEx (TTM)55.00K USD
FCF Margin-3832.13%
FCF Yield-3.86%
Net Debt-71.94M USD
Net Debt/EBITDA1.13
Balance Sheet
Debt/Equity0.00
Current Ratio7.42
Quick Ratio6.40
Book Value/Sh0.81 USD
Cash/Share1.52 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.00 USD
Upside (mean)+236.0%
Target Range10.00 USD – 75.00 USD
10.00+236.0% to mean75.00
# Analysts6
Ownership
Shares Out.62.15M
Float37.85M
Insiders7.97%
Institutions44.36%
Short Interest
Short Ratio2.8d
Short % Float4.30%
Short % Out.3.50%
Shares Short2.18M
Short (prev mo.)2.43M
Technical
SMA 5012.66 (-22.4%)
SMA 2008.223 (+19.4%)
Beta1.45
S&P 52W Chg15.78%
Avg Vol (30d)894.51K
Avg Vol (10d)938.36K
Technical Indicators
RSI (14)26.2
MACD-0.7679
MACD Signal-0.5129
MACD Hist.-0.2550
BB Upper14.58 USD
BB Middle11.81 USD
BB Lower9.031 USD
BB Width47.03%
ATR (14)0.6718 USD
Vol Ratio (20d)1.43x